Soligenix Reports Positive Phase 2a Extension Results for Psoriasis Treatment SGX302

Soligenix Inc. has announced extended top-line results from its Phase 2a clinical trial of SGX302 for mild-to-moderate psoriasis, reporting that the investigational therapy was well tolerated with no drug-related adverse events in the latest cohort. The company's progress into an extension cohort with an improved topical gel formulation marks another step forward for this first-in-class photodynamic therapy.

The Phase 2a trial has progressed into an extension cohort that enrolled four additional patients treated with an optimized gel formulation of SGX302. According to the company, this improved formulation was designed to enhance the patient experience through easier dispensation and skin application while maintaining therapeutic efficacy. Patients applied SGX302 gel to psoriasis lesions twice weekly over an 18-week treatment period, consistent with previous study phases.

SGX302 utilizes visible light-activated synthetic hypericin, representing a novel photodynamic therapy mechanism that distinguishes it from existing psoriasis treatments. The therapy's noncarcinogenic profile addresses significant safety concerns associated with some current psoriasis treatments, particularly those involving ultraviolet light exposure. This safety advantage could position SGX302 as a preferable option for long-term management of chronic psoriasis.

The clinical improvements observed with the optimized formulation underscore SGX302's potential as a targeted treatment for psoriasis lesions. As a late-stage biopharmaceutical company focused on rare diseases with unmet medical needs, Soligenix's progress with SGX302 addresses a significant gap in psoriasis treatment options. The company's latest news and updates are available through its newsroom at https://ibn.fm/SNGX.

For the broader biotechnology sector, Soligenix's continued positive results with SGX302 demonstrate the viability of novel photodynamic approaches in dermatology. The specialized communications platform BioMedWire, which focuses on biotechnology and biomedical sciences developments, provides additional industry context at https://www.BioMedWire.com. The platform's full terms of use and disclaimers are available at https://www.BioMedWire.com/Disclaimer.

The implications of SGX302's development extend beyond immediate clinical applications to potentially influence treatment paradigms for chronic skin conditions. As psoriasis affects millions worldwide with limited long-term treatment options, therapies offering improved safety profiles and targeted mechanisms could significantly enhance patient quality of life. The continued advancement of SGX302 through clinical development represents progress toward addressing these unmet needs while contributing to innovation in dermatological therapeutics.